Skip to main content

Amicus scraps plans for $600M gene therapy spinoff due to 'challenging environment'

With the deal off, Amicus will layoffs about 7% of its workforce and streamline operations in order to reach profitability.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.